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Abstract
Purpose—To describe viral retinitis following intravitreal and periocular corticosteroid
administration.
Methods—Retrospective case series and comprehensive literature review.
Results—We analyzed 5 unreported and 25 previously published cases of viral retinitis
following local corticosteroid administration. Causes of retinitis included 23 CMV (76.7%), 5
HSV (16.7%), and 1 each VZV and unspecified (3.3%). Two of 22 tested patients (9.1%) were
HIV positive. Twenty-one of 30 (70.0%) cases followed one or more intravitreal injections of
triamcinolone acetonide (TA), 4 (13.3%) after one or more posterior sub-Tenon injections of TA,
3 (10.0%) after placement of a 0.59-mg fluocinolone acetonide implant (Retisert), and 1 (3.3%)
each after an anterior subconjunctival injection of TA (together with IVTA), an anterior chamber
injection, and an anterior sub-Tenon injection. Mean time from most recent corticosteroid
administration to development of retinitis was 4.2 months (median 3.8; range 0.25–13.0). Twelve
patients (40.0%) had type II diabetes mellitus. Treatments used included systemic antiviral agents
(26/30, 86.7%), intravitreal antiviral injections (20/30, 66.7%), and ganciclovir intravitreal
implants (4/30, 13.3%).
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Conclusions—Viral retinitis may develop or reactivate following intraocular or periocular
corticosteroid administration. Average time to development of retinitis was 4 months, and CMV
was the most frequently observed agent. Diabetes was a frequent co-morbidity and several patients
with uveitis who developed retinitis were also receiving systemic immunosuppressive therapy.
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Herpetic retinitis is an uncommon, yet vision-threatening infection. In immunocompetent
patients, necrotizing retinitis is caused most often by either varicella zoster virus (VZV) or
herpes simplex virus (HSV).1,2 In immunocompromised patients, such as those with the
acquired immune deficiency syndrome (AIDS), cytomegalovirus (CMV) is an important
cause of retinitis.3–5 Regardless of cause, prompt diagnosis and treatment are required to
prevent vision loss.
While uncommon, the development of active viral retinitis following intraocular or
periocular corticosteroid injection has been described. In 2002, Dalessandro and colleagues
reported reactivation of CMV retinitis in a 45-year-old HIV-positive man 2 months
following a sub-Tenon injection of 40mg of triamcinolone acetonide for immune recovery
uveitis.6 Since that report, 19 studies describing 24 additional patients have appeared in the
literature (Table 1).7–25 The present report presents 5 new cases and includes a
comprehensive review of the occurrence and management of viral retinitis following
intraocular and periocular corticosteroid administration.
Methods
Cases were solicited by email from the members of the American Uveitis Society and the
Francis I. Proctor Foundation. A retrospective chart review was performed on 5 previously
undescribed patients who developed viral retinitis following intraocular or periocular
corticosteroid administration. Case reports for these 5 patients are presented. A MEDLINE
search using the terms “retinitis AND corticosteroid” was conducted to identify relevant
literature published after 1950. Additional studies were identified by reviewing the
references in the relevant articles selected from the aforementioned search. The
demographic and clinical features of both the newly described and previously reported cases
are summarized and discussed.
Results: Previously Unreported Case Descriptions (Table 1 and Figure 1)
Case 1
A 65-year-old Asian man with Vogt-Koyanagi-Harada (VKH) disease on infliximab,
methotrexate, and prednisone received both an anterior subcon-junctival and an intravitreal
triamcinolone acetonide injection (4 mg) following an uneventful cataract surgery on his
right eye. Seven weeks following surgery he presented with decreased vision to 20/200 in
the operated eye. Posterior segment examination revealed an area of active retinitis. An
aqueous chamber polymerase chain reaction (PCR) sample was positive for CMV
deoxynucleic acid (DNA). The patient's infliximab was discontinued and he was treated
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with both intravitreal ganciclovir and oral valganciclovir. Over the following 2 months the
patient's retinitis resolved and his vision improved to 20/40. His uveitis and retinitis
remained inactive on methotrexate and low-dose oral prednisone, and off antiviral agents.
Vision at last visit more than 1 year following the development of CMV retinitis was stable
at 20/40.
Case 2
A 37-year-old Caucasian woman with a history of idiopathic bilateral posterior uveitis and
persistent CME treated with infliximab and mycophenolate mofetil underwent fluocinolone
acetonide implant placements in both eyes. Follow-up examinations were performed every
2–4 months following placement. Approximately 12 months after insertion, the patient
presented with decreased vision from 20/40 to 20/80 in the right eye and necrotizing retinitis
was seen in the macula. Aqueous PCR was positive for CMV DNA. Infliximab and
mycophenolate mofetil were discontinued and the patient was treated with both intravitreal
foscarnet and oral valganciclovir. Over the following 2 months the patient's retinitis
resolved. Although the patient's CMV retinitis remained inactive, she subsequently
developed hypotony, and visual acuity in the affected eye at last visit was 20/80.
Case 3
A 63-year-old Caucasian man with unilateral granulomatous panuveitis and persistent CME
in the left eye presented with vision of 10/125 and was treated with two consecutive
posterior sub-Tenon injections of 40 mg triamcinolone acetonide. Vision initially improved
to 20/25, but 2 months later decreased to 20/40. Examination of the posterior segment
revealed vitritis, sheathing of the retinal arteries, and numerous punctate, yellowish retinal
infiltrates. Aqueous PCR was positive for CMV DNA. The patient was treated with
intravenous ganciclovir and oral prednisone, but the retinal lesions persisted and pars plana
vitrectomy (PPV) was performed. Retinal detachment developed 10 months after the
vitrectomy and vision at the patient's last visit 7 years later was 20/200.
Case 4
A 72-year-old Caucasian man received a 4-mg intravitreal injection of triamcinolone
acetonide for a branch retinal vein occlusion (BRVO) in the left eye. Approximately 1
month later, the patient returned with decreased vision in the left eye to 20/60. Fundus
examination revealed necrotizing retinitis in the macula and midperiphery. A vitreous PCR
was positive for CMV DNA. The patient was treated with four weekly intravitreal injections
of ganciclovir and while the retinitis responded to therapy, the vision remained limited to
counting fingers in the affected eye.
Case 5
A 37-year-old Caucasian woman with chronic idiopathic iridocyclitis in her left eye received
an anterior sub-Tenon injection of triamcinolone acetonide (10 mg) for refractory
inflammation. Two months later she developed active retinitis in the left eye. A presumed
diagnosis of acute retinal necrosis (ARN) was made, and she was placed on 800mg
acyclovir 5 times daily and given an intravitreal injection of ganciclovir. The retinitis
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became inactive with therapy, but there was marked retinal scarring with epiretinal
membrane formation and she subsequently developed a nasal BRVO a month later with
decreased vision to 20/200. Her visual acuity 3 years later remained stable at 20/200 in the
affected eye.
Discussion
We provided clinical descriptions of 5 previously unpublished cases of viral retinitis
following local corticosteroid administration. The mean age of patients was 55 years
(median: 63 years, range 37–72 years). Three out of 5 patients (60.0%) were male.
Indications for the corticosteroid included cataract surgery in a patient with uveitis (1),
uveitic CME (2), BRVO (1), and refractory uveitic inflammation (1). There was one 4-mg
intravitreal triamcinolone acetonide (IVTA) injection, 1 fluocinolone acetonide implant, 2
cases of sub-Tenon TA injections (1 anterior and 1 posterior), and 1 case that received both
a 4-mg IVTA injection and a 4-mg anterior subconjunctival TA injection. The mean time
from corticosteroid dosing to onset of viral retinitis was 4.2 months (median: 2 months,
range: 1.3–13 month). Four cases were CMV retinitis comfirmed by aqueous PCR, and 1
case was diagnosed clinically as ARN, but did not have confirmatory PCR. At last follow-up
visit (range: 2–84 months), none of the 5 cases had visual outcome better than or equal to
20/40, and 3 of the cases had visual acuity at last visit worse than or equal to 20/200. The
retinitis involved the macula in 2 cases (cases 2 and 4), and the visual acuity at last visit was
complicated by hypotony (20/80) and BRAO (CF), respectively. Case 1 did not involve the
macula and had an outcome visual acuity at last visit of 20/70. Case 3 was complicated by a
subsequent retinal detachment visual acuity at last visit of 20/200. Finally, case 5 was
complicated by a nasal BRVO with marked retinal scarring and epiretinal membrane
formation, with a visual acuity at last visit of 20/200. Three out of the 5 cases (60.0%) were
treated with intravitreal and oral antivirals, 1 (20.0%) with intravenous antivirals alone, and
1 (20.0%) with intravitreal antivirals alone.
Twenty previously published reports, including 25 patients with viral retinitis following
local corticosteroid administration, were identified through our review of the literature.7–25
Taken together with our case series, we identified a total of 30 cases (Table 1). The mean
age of all 30 patients was 62.6 years (median 65.5 years; range: 22-84 years) with a slight
male predominance (63.3%). Two patients had a diagnosis of HIV (2/22, 9.1%), and type 2
diabetes mellitus was present in 12/30 patients (40.0%). Of the 12 diabetic patients, 7
(58.3%) were treated with local corticosteroids for reasons other than diabetic macular
edema. Overall, the most common indication for corticosteroid use was retinal vein
occlusion (8/30, 26.7%), followed by persistent inflammation (5/30, 16.7%), diabetic
macular edema (6/30, 20.0%), uveitic CME (4/30, 13.3%), choroidal neovascularization due
to age-related macular degeneration (3/30, 10.0%), and immune recovery uveitis (2/30
6.7%). Both cases of immune recovery uveitis had a history of CMV retinitis that
reactivated. Cytomegalovirus was the most common etiologic agent (23/30, 76.7%),
followed by herpes simplex virus (5/30, 16.7%) and varicella zoster virus (1/30, 3.3%). The
viral cause was not identified in 1 case (1/30, 3.3%). Doses of corticosteroid used ranged
from 1.5 to 40mg, with the majority of cases involving doses between 1.5 and 20mg (20/26,
77.0.%). Three of the cases involved the use of fluocinolone acetonide implant. The mean
Takakura et al. Page 4
Ocul Immunol Inflamm. Author manuscript; available in PMC 2014 September 04.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
time from corticosteroid administration to diagnosis of retinitis was 3.9 months for
intravitreal injections (median 4.0 months, range 1.3–7 months). For posterior sub-Tenon
injections, the mean time was 1.8 months (median: 2 months, range 0.25–3 months), 2
months for the 1 case following anterior sub-Tenon injection, 0.5 months for the 1 case
following anterior chamber TA, and 10.3 months for the fluocinolone acetonide implants
(Retisert) (median: 13 months, range 5–13 months). A majority of the cases did not involve
the macula (23/29, 79.3%). Visual acuity at the time of diagnosis varied, with 6/30 (20.0%)
patients having vision better than or equal to 20/40 while 16/ 30 (53.3%) had vision worse
than or equal to 20/200. Although half of patients were treated with both systemic and
intravitreal antivirals (14/30, 46.6%), others were treated either with systemic antivirals
alone (10/30, 33.3%), or with intravitreal antivirals alone (4/30, 13.3%). Mean follow-up
time was 13.7 months (median: 8.0 months, range: 1–84 months). Visual acuity at last visit
tended to be poor, with half (58.4%) of all cases having a best-corrected vision worse than
or equal to 20/200. Only 5/24 (20.8%) cases had a visual acuity at last visit better than or
equal to 20/40.
Viral retinitis occurred in two-thirds of eyes following one or more intravitreal
corticosteroid injections (21/30, 70.0%). Eighteen out of 21 eyes (85.7%) had one previous
injection of intravitreal corticosteroid, 2/21 (9.5%) had two previous injections, and 1/21
(4.8%) had three previous injections. The mean time from last intravitreal injection to
identification of viral retinitis was 3.9 months (median 4.0 months, range 0.75–7 months). In
no instances did the authors describe removal of intravitreal corticosteroid or the
corticosteroid releasing implant following the development of retinitis.
Nine out of 30 patients (30.0%) were administered intravitreal or periocular corticosteroids
as part of the management of their uveitis. The mean age was 50.3 years (median 56 years;
range 22–77 years) and 2/3 were male. Six out of 9 (66.7%) patients had idiopathic uveitis,
2/9 (22.2%) had Behçet disease, and 1/9 (11.1%) had Vogt-Koyanagi-Harada disease. A
third of the cases involved intravitreal corticosteroids injections (3/9, 33.3%), another third
involved fluocinolone acetonide (Retisert) implants, 2 involved posterior sub-Tenon TA
injections, and 1 case involved an anterior sub-Tenon injection. After the diagnosis of viral
retinitis, there were variable modifications made to the patients' corticosteroid and/or non-
corticosteroid immunomodulating therapy. In one case, azathioprine was discontinued and
10mg of oral prednisone was continued.24 In a second case, infliximab was discontinued and
low-dose oral prednisone and methotrexate were continued. In a third case, both infliximab
and mycophenolate mofetil were discontinued. In a fourth case, azathioprine was
discontinued and high-dose oral prednisone and interferon-alpha were started.21 In the
remaining 5 cases no changes were made to their systemic therapy except for the addition of
an antiviral agent.The contribution of concurrent systemic corticosteroids and/or non-
corticosteroid immunosuppressive agents, including TNF inhibitors, to the development of
viral retinitis remains unclear, as viral infections have been reported to occur in patient on
such therapies.26,27 Overall, 5 out of 9 patients (55.6%) were treated with both antivirals and
systemic antivirals, 2/9 (22.2%) were treated with both intravitreal antivirals and an
intraocular ganciclovir implant, and 1 each was treated with either an intravenous or
intravitreal antiviral alone. In all 3 patients who received fluocinolone acetonide (Retisert)
implants, none of the implants were removed after the development of retinitis. The mean
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time from injection/ implantation of corticosteroid to development of retinitis was 5.3
months (median 3.5 months, range 0.25–13 months).
Of the 23 patients who had reported CMV retinitis following pericoular/intravitreal ocular
corticosteroid injections, all but 2 had no prior history of CMV retinitis. The 2 who did have
prior CMV retinitis were both HIV positive and were treated with local corticosteroid
injections to treat immune recovery uveitis with or without cystoid macular edema.19,28
During their initial CMV retinitis episode, both patients were placed on highly active
antiretroviral therapy (HAART) and antivirals, with their CD4 counts improving to 126 and
324 cells/mm3, respectively. They then developed IRU and were given local corticosteroid
injections (a 40-mg sub-Tenon TA and a 20-mg IVTA, respectively). The maintenance dose
of ganciclovir was continued for the first patient and discontinued in the second as there
were no active areas of CMV retinitis. Two and 3 months later, respectively, they presented
with reactivation of their CMV retinitis. That they reactivated despite the fact that their CD4
counts were elevated on HAART demonstrated that CMV retinitis can reactivate following
local corticosteroid administration—even in the setting of relative immune reconstitution.
Ten patients (10/27, 37.0%) who developed CMV retinitis following corticosteroid injection
did so in the setting of type 2 diabetes mellitus. The mean age of diabetic patients was 69.3
years (median 72.0 years, range 54–83 years), 9 out of 10 (90.0%) patients were male, and 4
out of 10 (40.0%) had corticosteroid injections for diabetic macular edema. In 9 out of 10
(90.0%) patients with diabetes, the viral retinitis was identified as CMV retinitis, and in 1
case (10.0%) the causative agent could not be identified. Radwan and colleagues recently
reported 2 cases and reviewed the literature on CMV retinitis in immunocompetent patients.
Of note, 6 of 12 previously reported patients (50%) had diabetes mellitus. 28 Although the
relationship between diabetes mellitus and the development of CMV retinitis is difficult to
discern, both Shah and associates and Radwan and colleagues suggested that the presence of
diabetic vasculopathy may have facilitated entry of CMV into the retina and thereby
promoted the development of retinitis.19,28 Others have reported that circulating CMV levels
tend to be higher in patients with diabetes mellitus.29
In summary, although uncommon, viral retinitis may develop or reactivate following
periocular or intravitreal corticosteroid administration. In three-quarters of affected eyes,
CMV was identified as the causative agent, and in two-thirds of cases corticosteroid was
given as an intravitreal injection. The average time between the injection of corticosteroid
and the development of retinitis was between 3 and 4 months. Systemic and/or intravitreal
antiviral agents were effective at controlling the retinitis in all patients, although vision at
the last visit was worse than 20/200 in 14 out of 24 eyes (58.4%) due either to the location
of the retinitis and/or the development of rhegmatogenous retinal detachment (4/24, 16.7%).
Approximately 40% (12/30) of patients had type 2 diabetes mellitus, a co-morbidity
previously noted to affect up to 50% of otherwise immunocompetent patients who
developed CMVretinitis.28 Several of the patients with uveitis who developed retinitis were
also receiving systemic immunosuppressive therapy. Hence, definitive proof of a causal role
for periocular or intraocular corticosteroids in the development of viral retinitis has yet to be
provided.
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Figure 1.
Color fundus photographs of the 5 previously unreported cases of viral retinitis following
intraocular or periocular corticosteroid injection. Cases 1–4 were cytomegalovirus (CMV)
retinitis. Case 5 was diagnosed clinically as acute retinal necrosis, although the causative
virus was not identified. The retinitis resolved in all cases in response to antiviral therapy.
Takakura et al. Page 9
Ocul Immunol Inflamm. Author manuscript; available in PMC 2014 September 04.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Takakura et al. Page 10
Ta
bl
e 
1
Su
m
m
ar
y 
of
 P
re
vi
ou
sly
 R
ep
or
te
d 
an
d 
Cu
rre
nt
 C
as
es
 o
f V
ira
l R
et
in
iti
s F
ol
lo
w
in
g 
In
tra
oc
ul
ar
 a
nd
 P
er
io
cu
la
r C
or
tic
or
ste
ro
id
 In
jec
tio
n.
A
ut
ho
r 
(Y
ea
r)
A
ge
 (y
ea
rs)
G
en
de
r
H
IV
 st
at
us
In
di
ca
tio
n 
fo
r 
co
rt
ic
os
te
ro
id
D
os
e 
/ R
ou
te
Ti
m
e 
fr
om
co
rt
ic
os
te
ro
id
 d
os
in
g
to
 r
et
in
iti
s (
mo
nt
hs
)
Es
ta
bl
ish
ed
 D
ia
gn
os
is
(M
eth
od
)
Zo
ne
 In
vo
lv
ed
(1=
ma
cu
la,
2=
m
id
pe
ri
ph
er
y,
3=
ou
te
r p
er
ip
he
ry
)
V
isi
on
 w
he
n 
re
tin
tit
is
fir
st
 d
ia
gn
os
ed
Tr
ea
tm
en
t
D
ur
at
io
n 
of
Fo
llo
w
-U
p
(m
on
th
s)
V
isi
on
 a
t l
as
t v
isi
t
Pr
ev
io
us
ly
 P
ub
lis
he
d 
C
as
es
D
al
es
sa
nd
ro
 e
t a
l, 
(20
02
)6
45
M
+
Im
m
un
e 
re
co
ve
ry
 u
ve
iti
s
40
m
g 
PS
T 
TA
2.
0
CM
V
 re
tin
iti
s (
NR
)
2
20
/1
00
In
tra
ve
no
us
 g
an
cy
cl
ov
ir
18
“
re
co
v
er
ed
 h
ab
itu
al
 v
isu
al
ac
u
ity
”
 
 
 
 
Sa
id
el
 et
 a
l, 
(20
05
)7
75
M
-
D
M
E
4m
g 
IV
TA
4.
0
CM
V
 re
tin
iti
s (
PC
R)
1
20
/4
00
In
tra
vi
tre
al
 g
an
cy
cl
ov
ir,
 v
an
co
m
yc
in
,
ce
fta
zi
di
m
e,
 T
he
n 
va
lg
an
ci
cl
ov
ir,
 to
pi
ca
l
pr
ed
ni
so
lo
ne
, R
ep
ea
te
d 
In
tra
vi
tre
al
ga
nc
yc
lo
vi
r
6
20
/4
00
A
gg
er
m
an
n 
et
 a
l, 
(20
06
)8
69
M
N
R
CM
E/
CR
V
O
 d
ue
 to
 F
ac
to
r V
Le
id
en
4m
g 
IV
TA
0.
75
H
SV
 re
tin
iti
s (
ser
olo
gy
)
1
N
LP
In
tra
vi
tre
al
 a
nt
ib
io
tic
s, 
in
tra
vi
tre
al
co
rt
ic
os
te
ro
id
s, 
PP
V
, P
K
, T
he
n 
sy
ste
m
ic
an
tiv
ira
l t
he
ra
py
24
N
LP
 
 
 
 
To
h 
et
 a
l, 
(20
06
)9
62
F
N
R
CN
V
M
 / 
A
M
D
4m
g 
IV
TA
6.
0
H
SV
 re
tin
iti
s (
ser
olo
gy
)
2
6/
18
In
tra
ve
no
us
 a
cy
cl
ov
ir,
 T
op
ic
al
 ti
m
ol
ol
,
la
ta
no
pr
os
t, 
O
ra
l a
cy
cl
ov
ir
3
6/
36
 
 
D
el
yf
er
 e
t a
l, 
(20
07
)1
0
77
M
-
CN
V
M
 / 
A
M
D
20
m
g 
IV
TA
4.
0
CM
V
 re
tin
iti
s (
ser
olo
gy
+P
CR
)
2
CF
 a
t 1
.8
m
In
tra
vi
tre
al
, i
nt
ra
ve
no
us
, v
al
ga
nc
ic
lo
vi
r
6
20
/2
00
59
M
-
CR
V
O
 / 
D
M
E
8m
g 
IV
TA
 th
re
e 
tim
es
o
v
er
 3
 m
on
th
 in
te
rv
al
3 
(af
ter
 3r
d I
VT
A)
CM
V
 re
tin
iti
s (
PC
R)
1
20
/2
00
In
tra
ve
no
us
 g
an
ci
cl
ov
ir,
 v
al
ga
nc
ic
lo
vi
r
3
20
/4
00
Fu
ru
ka
w
a 
et
 a
l, 
(20
07
)1
1
54
F
-
D
M
E
10
m
g 
IV
TA
4.
0
CM
V
 re
tin
iti
s (
ser
olo
gy
+P
CR
)
2
1
In
tra
ve
no
us
 p
an
ip
en
em
, v
an
co
m
yc
in
/
pa
ni
pe
ne
m
, I
nt
ra
ve
no
us
 g
an
ci
cl
ov
ir,
In
tra
vi
tre
ou
s f
os
ca
rn
et
, V
itr
ec
to
m
y 
an
d
sil
ic
on
e 
oi
l t
am
po
na
de
14
0.
5
 
 
 
 
H
su
 e
t a
l, 
(20
07
)1
2
77
M
-
D
M
E
4m
g 
IV
TA
1.
5
CM
V
 re
tin
iti
s (
PC
R)
2
3/
20
0
V
al
ga
nc
yc
lo
vi
r
1
20
/4
00
 
 
 
 
 
U
fr
et
-V
in
ce
nt
y 
et
 a
l,
(20
07
)1
3
65
M
N
R
U
ve
iti
c 
CM
E 
/ B
eh
ce
t's
 d
ise
as
e
FA
 im
pl
an
t
53
 (a
fte
r 1
st 
im
pla
nt)
, 5
(af
ter
 2n
d i
mp
lan
t)
CM
V
 re
tin
iti
s (
“c
lin
ica
l
di
ag
no
sis
”)
2
20
/5
0
In
tra
vi
tre
al
 fo
sc
ar
ne
t, 
ga
nc
ic
lo
vi
r i
m
pl
an
t
5
20
/4
0
 
 
 
 
Pa
rk
 e
t a
l, 
(20
08
)1
4
77
F
-
CR
V
O
 / 
CM
E 
du
e 
to
 H
TN
4m
g 
IV
TA
4.
0
CM
V
 re
tin
iti
s (
PC
R)
2
LP
In
tra
ve
no
us
 a
cy
cl
ov
ir,
 in
tra
vi
tre
ou
s
ga
nc
ic
lo
vi
r
4
H
M
 
Se
ki
ry
u 
et
 a
l, 
(20
08
)1
5
63
M
N
R
B
R
V
O
 / 
D
M
E
4m
g 
IV
TA
7.
0
CM
V
 re
tin
iti
s (
PC
R)
2
0.
1
In
tra
ve
no
us
 a
cy
cl
ov
ir,
 In
tra
ve
no
us
ga
nc
yc
lo
vi
r, 
va
lg
an
cy
cl
ov
ir
1
0.
6
 
R
am
ai
ya
 e
t a
l, 
(20
10
)1
6
22
M
-
Id
io
pa
th
ic
 p
an
uv
ei
tis
FA
 Im
pl
an
t
13
.0
H
SV
 re
tin
iti
s (
PC
R)
2
H
M
In
tra
vi
tre
al
 fo
sc
ar
ne
t, 
In
tra
ve
no
us
 a
cy
cl
ov
ir,
O
ra
l v
al
cy
cl
ov
ir
N
R
H
M
 
Ba
bi
uc
h 
et
 a
l, 
(20
10
)1
7
77
M
N
R
Id
io
pa
th
ic
 ir
iti
s
40
m
g 
PS
T 
TA
0.
25
CM
V
 re
tin
iti
s (
ser
olo
gy
+P
CR
)
2
20
/4
0
V
itr
ec
to
m
y,
 e
nd
ol
as
er
, I
nt
ra
vi
tre
al
ga
nc
ic
lo
vi
r, 
G
an
ci
cl
ov
ir 
im
pl
an
t
N
R
N
R
 
 
 
C
ha
ng
 et
 a
l, 
(20
10
)1
8
75
F
-
Po
st
-c
at
ar
ac
t i
nf
la
m
m
at
io
n
1.
5m
g 
an
te
rio
r c
ha
m
be
r
TA
0.
5
H
SV
 re
tin
iti
s (
ser
olo
gy
)
2
20
/4
C
In
tra
ve
no
us
 a
cy
cl
ov
ir,
 to
pi
ca
l p
re
dn
iso
lo
ne
an
d 
at
ro
pi
ne
, O
ra
l p
re
dn
iso
ne
 a
nd
 o
ra
l
v
al
ac
yc
lo
vi
r V
itr
ec
to
m
y,
 la
se
r r
et
in
op
ex
y 
an
d
ga
s t
am
po
na
de
12
20
/5
0
 
 
 
 
 
Sh
ah
 et
 a
l, 
(20
10
)1
9
62
M
N
R
B
R
V
O
 / 
D
M
E
20
m
g 
IV
TA
 x
2
6.
5
CM
V
 re
tin
iti
s (
PC
R)
2
20
/4
00
V
al
ac
yc
lo
vi
r, 
V
itr
ec
to
m
y,
 e
nd
ol
as
er
 a
nd
sil
ic
on
e 
oi
l, 
Th
en
 V
al
ga
nc
ic
lo
vi
r
N
R
N
R
43
M
+
CM
E 
fro
m
 IR
U
, h
ist
or
y 
of
 C
M
V
re
tin
tis
 a
nd
 H
IV
 re
ce
nt
ly
 st
ar
te
d
o
n
 H
A
A
RT
20
m
g 
IV
TA
3.
3
CM
V
 re
tn
iti
s (
pri
or 
his
tor
y/
cl
in
ic
al
 a
pp
ea
ra
nc
e)
2
20
/4
0
V
al
ga
nc
yc
lo
vi
r
N
R
N
R
Ocul Immunol Inflamm. Author manuscript; available in PMC 2014 September 04.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Takakura et al. Page 11
A
ut
ho
r 
(Y
ea
r)
A
ge
 (y
ea
rs)
G
en
de
r
H
IV
 st
at
us
In
di
ca
tio
n 
fo
r 
co
rt
ic
os
te
ro
id
D
os
e 
/ R
ou
te
Ti
m
e 
fr
om
co
rt
ic
os
te
ro
id
 d
os
in
g
to
 r
et
in
iti
s (
mo
nt
hs
)
Es
ta
bl
ish
ed
 D
ia
gn
os
is
(M
eth
od
)
Zo
ne
 In
vo
lv
ed
(1=
ma
cu
la,
2=
m
id
pe
ri
ph
er
y,
3=
ou
te
r p
er
ip
he
ry
)
V
isi
on
 w
he
n 
re
tin
tit
is
fir
st
 d
ia
gn
os
ed
Tr
ea
tm
en
t
D
ur
at
io
n 
of
Fo
llo
w
-U
p
(m
on
th
s)
V
isi
on
 a
t l
as
t v
isi
t
73
F
N
R
ER
M
 / 
CM
E
20
m
g 
IV
TA
25
V
ZV
 re
tin
iti
s (
his
tor
y o
f V
ZV
ke
ra
to
uv
ei
tis
 a
nd
 re
sp
on
se
 to
tr
ea
tm
en
t)
2
20
/4
00
In
tra
vi
tre
al
 fo
sc
ar
ne
t a
nd
 v
al
ac
yc
lo
vi
r
N
R
N
R
To
yo
ka
w
a 
et
 a
l, 
(20
10
)2
0
83
M
-
CN
V
M
 / 
A
M
D
20
m
g 
PS
T 
TA
3.
0
CM
V
 re
tin
iti
s (
PC
R)
2
0.
3
O
ra
l v
al
ac
yl
ov
ir,
 o
ra
l p
re
dn
iso
ne
 v
itr
ec
to
m
y,
in
tra
vi
tre
al
 a
cy
cl
ov
ir
5
0.
1
 
 
 
 
 
Tu
ga
l-T
ut
ku
n 
et
 a
l
(20
10
)2
1
30
M
B
eh
ce
t's
 P
an
uv
ei
tis
IV
TA
 d
os
e 
N
R
3.
5
CM
V
 re
tin
iti
s (
ser
olo
gy
+P
CR
)
1,
2,
3
20
/2
00
In
tra
vi
tre
al
 g
an
ci
cl
ov
ir 
x 
2,
 in
tra
ve
no
us
ga
nc
ic
lv
ir 
x 
5 
w
ks
, a
za
th
io
pr
in
e c
ha
ng
ed
 to
in
te
rfe
ro
n 
al
ph
a 
2a
8
20
/6
0
 
 
 
V
er
te
s e
t a
l, 
(20
10
)2
2
78
F
-
B
R
V
O
 / 
CM
E
4m
g 
IV
TA
3.
0
CM
V
 re
tin
iti
s (
ser
olo
gy
+P
CR
;
2
20
/4
C
In
tra
ve
no
us
 g
an
ci
cl
ov
ir,
 O
ra
l g
an
ci
cl
ov
ir 
an
d
ac
et
az
ol
am
id
e,
 to
pi
ca
l d
or
zo
la
m
id
e/
tim
ol
ol
,
pr
ed
ni
so
lo
ne
 in
tra
vi
tre
ou
s g
an
ci
cl
ov
ir,
 T
he
n
v
itr
ec
to
m
y,
 e
nd
ol
as
er
8
20
/2
5
 
 
 
 
 
H
an
 e
t a
l, 
(20
11
)2
3
56
M
-
D
M
E
4m
g 
IV
TA
5.
0
u
n
sp
ec
ifi
ed
 v
ira
l r
et
in
iti
s
(se
rol
og
y+
cli
nic
al 
ap
pe
ara
nc
e)
2
20
/2
00
In
tra
ve
no
us
 a
cy
cl
ov
ir,
 o
ra
l v
al
ac
yc
lo
vi
r, 
or
al
as
pi
rin
 a
nd
 o
ra
l/t
op
ic
al
 st
er
oi
ds
, b
ar
rie
r l
as
er
,
v
itr
ec
to
m
y,
 E
RM
 re
m
ov
al
 c
om
bi
ne
d 
w
ith
ca
ta
ra
ct
 o
pe
ra
tio
n
12
20
/4
0
 
 
 
Za
bo
ro
w
sk
i (2
01
3)2
4
56
F
-
Id
io
pa
th
ic
 p
an
uv
ei
tis
 / 
U
ve
iti
c
CM
E
4m
g 
IV
TA
6.
0
CM
V
 re
tin
iti
s (
PC
R;
2
CF
A
za
th
io
pr
in
e 
di
sc
on
tin
ue
d,
 In
tra
vi
tre
al
ga
nc
ic
lo
vi
r t
w
ic
e 
w
ee
kl
y 
fo
r t
hr
ee
 w
ee
ks
 (2
m
g)
2
N
R
 
 
 
 
 
 
 
G
up
ta
 (2
01
3)2
70
F
-
D
M
E
IV
TA
 d
os
e 
N
R
4.
0
CM
V
 re
tin
iti
s (
PC
R)
2
CF
Sy
ste
m
ic
 a
cy
cl
ov
ir,
 to
pi
ca
l s
te
ro
id
 th
er
ap
y,
in
tra
vi
tre
al
 fo
sc
ar
ne
t, 
va
la
cy
cl
ov
ir,
 in
tra
vi
tre
al
fo
sc
ar
ne
t x
 2
, g
an
ci
cl
ov
ir 
im
pl
an
t
32
CF
60
M
-
D
M
E
IV
TA
 N
R
6.
0
CM
V
 re
tin
iti
s (
PC
R)
N
R
20
/4
00
In
tra
vi
tre
al
 fo
sc
ar
ne
t, 
sy
ste
m
ic
 v
al
ga
nc
ic
lo
vi
r,
ga
nc
ilc
ov
ir 
im
pl
an
t
N
R
20
/3
00
84
F
-
B
R
V
O
IV
TA
 N
R
6.
0
CM
V
 re
tin
iti
s (
PC
R)
2
20
/1
50
In
tra
vi
tre
al
 fo
sc
ar
ne
t, 
sy
ste
m
ic
 v
al
ac
lo
vi
r,
sy
ste
m
ic
 v
al
ga
nc
ic
lo
vi
r
19
H
M
C
ur
re
nt
 C
as
es
(1)
66
M
-
V
K
H
 w
ith
 st
er
oi
d-
in
du
ce
d
ca
ta
ra
ct
s 
an
d 
oc
ul
ar
 h
yp
er
te
ns
io
n,
IV
TA
 g
iv
en
 d
ur
in
g 
ca
ta
ra
ct
su
rg
er
y
4m
g 
IV
TA
 &
 A
SC
TA
1.
8
CM
V
 re
tin
iti
s (
PC
R)
2
20
/2
00
In
tra
vi
tre
al
 g
an
ci
cl
ov
ir,
 o
ra
l v
al
ga
nc
ic
lo
vi
r,
m
et
ho
tre
xa
te
 a
nd
 lo
w
 d
os
e 
or
al
 p
re
dn
iso
ne
2
20
/7
0
(2)
37
F
-
B
ila
te
ra
l i
di
op
at
hi
c 
po
ste
rio
r
u
v
ei
tis
 c
om
pl
ic
at
ed
 b
y 
CM
E 
/
re
tin
al
 v
as
cu
lit
is
FA
 Im
pl
an
t
13
.0
CM
V
 re
tin
iti
s (
PC
R)
1
20
/8
0
In
tra
vi
tre
al
 fo
sc
ar
ne
t, 
O
ra
l v
al
ga
nc
ic
lo
vi
r
2
20
/1
00
(3)
63
M
-
G
ra
nu
lo
m
at
ou
s u
ve
iti
s w
ith
 C
M
E
40
m
g 
IV
TA
 x
 2
3.
0
CM
V
 re
tin
iti
s (
PC
R)
2
20
/6
0
In
tra
ve
no
us
 g
an
ci
cl
ov
ir,
 O
ra
l p
re
dn
iso
ne
,
PP
V
84
20
/2
00
(4)
72
M
N
R
B
R
V
O
4m
g 
IV
TA
1.
3
CM
V
 re
tin
iti
s (
PC
R)
2
20
/6
0
In
tra
vi
tre
al
 g
an
ci
cl
ov
ir
12
CF
(5)
37
F
-
Ch
ro
ni
c 
id
io
pa
th
ic
 ir
id
oc
yc
lit
is
10
m
g 
A
ST
 T
A
2.
0
H
SV
 re
tin
iti
s (
PC
R)
2
20
/3
0
A
cy
cl
ov
ir,
 In
tra
vi
tre
al
 g
an
ci
cl
ov
ir
36
20
/2
00
Su
m
m
ar
y
M
ea
n:
 6
2.
6 
yr
s
M
al
e:
Fe
m
al
 e
: 1
9:
11
H
IV
 +
: 2
/2
2
(9.
1%
)
R
V
O
: 8
/3
0 
(26
.7%
)
1.
5-
4m
g:
 1
2/
26
 (4
6.2
%
)
M
ea
n:
 4
.2
 m
on
th
s
C
M
V
 re
tin
iti
s:
 2
3/
30
 (7
6.7
%
)
Zo
ne
 1
 :
5/
29
(17
.2%
)
≥ 
20
/4
0:
 6
/3
0(2
0.0
%
)
Sy
st
em
ic
 a
lo
ne
: 1
0/
30
 (3
3.3
%
)
M
ea
n:
 1
3.
7 
m
on
th
s
≥ 
20
/4
0:
 5
/2
4 
(20
.8%
)
M
ed
ia
n:
 6
5.
5 
yr
s
%
M
al
e:
 6
3.
3
D
M
E:
 6
/3
0 
(20
.0%
)
8-
20
 m
g:
 8
/2
6 
(30
.8%
)
M
ed
ia
n:
 3
.8
 m
on
th
s
H
SV
 re
tin
iti
s:
 5
/3
0 
(16
.7%
)
Zo
ne
 2
: 2
3/
29
(79
.3%
)
<
 2
0/
40
 &
 >
20
/2
00
: 8
/3
0
26
.7
%
)
IV
T 
al
on
e:
 4
/3
0 
(13
.3%
)
M
ed
ia
n:
 8
.0
 m
on
th
s
<
 2
0/
40
 &
 >
20
/2
00
: 5
/2
4
(20
.8%
)
R
an
ge
: 2
2.
0-
84
.0
 y
rs
U
ve
iti
c C
M
E:
 4
/3
0 
(13
.3%
)
40
m
g:
 3
/2
6(1
1.5
%
)
R
an
ge
: 0
.2
5-
13
.0
 m
on
th
s
V
ZV
 re
tin
iti
s:
 1
/3
0(3
.3%
)
Zo
ne
 1
+2
+3
: 1
/2
9
(3.
5%
)
≤2
0/
20
0:
 1
6/
30
(53
.3%
)
Bo
th
 sy
st
em
ic
 a
nd
 IV
T:
 1
6/
30
 (5
3.4
%
R
an
ge
: 1
 to
 8
4
m
o
n
th
s
≤2
0/
20
0:
 1
4/
24
 (5
8.4
%
)
C
N
V
M
 d
ue
 to
 A
M
D
: 3
/3
0
(10
.0%
) I
RU
: 2
/30
 (6
.7%
)
FA
 Im
pl
an
t: 
3/
26
(11
.5%
)
U
ns
pe
ci
fie
d:
 1
/3
0(3
.3%
)
O
th
er
: 7
/3
0 
(23
.3%
)
R
an
ge
 o
f D
os
es
:
1.
5-
40
m
g
Ocul Immunol Inflamm. Author manuscript; available in PMC 2014 September 04.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Takakura et al. Page 12
*
A
m
on
g 
th
e 
30
 to
ta
l c
as
es
, 1
2 
(40
.0%
) h
ad
 T
yp
e I
I D
iab
ete
s M
ell
itu
s a
nd
 2(
6.7
%)
 ha
d m
ali
gn
an
cie
s (
M
eta
sta
tic
 O
va
ria
n C
an
ce
r a
nd
 L
ym
ph
om
a)
A
SC
 T
A
 =
 A
nt
er
io
r S
ub
-C
on
jun
cti
va
l T
ria
mc
ino
lon
e A
cet
on
ide
, A
MD
 = 
Ag
e-r
ela
ted
 M
acu
lar
 D
eg
en
era
tio
n, 
BR
VO
 = 
Br
an
ch
 R
eti
na
l V
ein
 O
ccl
usi
on
, C
RV
O 
= C
en
tra
l R
eti
na
l V
ein
 O
ccl
usi
on
, C
ME
 = 
Cy
sto
id 
Ma
cu
lar
 Ed
em
a, 
CM
V 
= C
yto
Me
ga
loV
iru
s, C
NV
M 
= C
ho
roi
da
l
N
eo
V
as
cu
la
r M
em
br
an
e,
 D
M
E=
 d
ia
be
tic
Ocul Immunol Inflamm. Author manuscript; available in PMC 2014 September 04.
